Multiple sclerosis (MS) is a chronic demyelinating inflammatory disease of the central nervous system. It is the most common neurological disease in adults and women. The global multiple sclerosis drugs market is rapidly growing due to factors such as growing prevalence of MS, significant unmet needs, and promising pipeline molecules.
The report titled “Multiple Sclerosis Drugs Market - Growth, Future Prospects and Competitive Analysis, 2017–2025” offers strategic insights into the overall multiple sclerosis drugs market along with the market size and estimates for the duration 2015 to 2025. The research study covers in-depth analysis of market segments based on molecule type (biologics and small molecules), route of administration (oral therapeutic drugs, parenteral therapeutic drugs) and different geographical regions.
Geographically, the global multiple sclerosis drugs market is studied for the following regional markets:
Market size and forecast for these regional and country level markets are presented in this study for the period 2015-2025. Market growth rates for the forecast period 2017-2025 are also included in this report, considering 2016 as the base year.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario, pipeline analysis and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global multiple sclerosis drugs market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global multiple sclerosis drugs market. This report concludes with company profiles section that highlights major information about the key players engaged in global multiple sclerosis drugs market. In-depth competitive environment analysis and historical years (2015) market size data are also provided in the report.
Thus, the research study provides a holistic view of the global multiple sclerosis drugs market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.
Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions
Chapter 2 Executive Summary
2.1 Global Multiple Sclerosis Drugs Market Snapshot
2.2 Global Multiple Sclerosis Drugs Market, Molecule Type
2.3 Global Multiple Sclerosis Drugs Market, Route of Administration
2.4 Global Multiple Sclerosis Drugs Market Share, by Geography, 2016 (Value %)
Chapter 3 Multiple Sclerosis Drugs Market Analysis
3.1 Global Multiple Sclerosis Drugs Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.2 Challenges
3.2.3 Opportunities
3.3 Pipeline Analysis of Multiple Sclerosis Drugs Market
3.4 Epidemiology of Multiple Sclerosis
3.5 Attractive Investment Proposition
3.6 Competitive Landscape of Key Players in Multiple Sclerosis Drugs Market
Chapter 4 Global Multiple Sclerosis Drugs Market, by Molecule Type
4.1 Overview
4.2 Top 3 Countries
4.3 Biologics
4.4 Small Molecules
Chapter 5 Global Multiple Sclerosis Drugs Market, by Route of Administration Type
5.1 Overview
5.2 Top 3 Countries
5.3 Oral Therapeutic Drugs
5.4 Parenteral Therapeutic Drugs
Chapter 6 Global Multiple Sclerosis Drugs Market, by Geography
6.1 Preface
6.2 North America (U.S. & Canada)
6.2.1 North America Multiple Sclerosis Drugs Market, by Molecule Type, 2015-2025 (US$)
6.2.2 North America Multiple Sclerosis Drugs Market, by Route of Administration, 2015-2025 (US$)
6.2.3 North America Multiple Sclerosis Drugs Market, by Country, 2015-2025 (US$)
6.3 Europe (U.K., Germany & Rest of Europe)
6.3.1 Europe Multiple Sclerosis Drugs Market, by Molecule Type, 2015-2025 (US$)
6.3.2 Europe Multiple Sclerosis Drugs Market, by Route of Administration, 2015-2025 (US$)
6.3.3 Europe Multiple Sclerosis Drugs Market, by Country, 2015-2025 (US$)
6.4 Asia Pacific (China, Japan and Rest of APAC)
6.4.1 Asia Pacific Multiple Sclerosis Drugs Market, by Molecule Type, 2015-2025 (US$)
6.4.2 Asia Pacific Multiple Sclerosis Drugs Market, by Route of Administration, 2015-2025 (US$)
6.4.1 Asia Pacific Multiple Sclerosis Drugs Market, by Country, 2015-2025 (US$)
6.5 Latin America (Brazil, Mexico and Rest of LATAM)
6.5.1 Latin America Multiple Sclerosis Drugs Market, by Molecule Type, 2015-2025 (US$)
6.5.2 Latin America Multiple Sclerosis Drugs Market, by Route of Administration, 2015-2025 (US$)
6.5.3 Latin America Multiple Sclerosis Drugs Market, by Country, 2015-2025 (US$)
6.6 Middle East and Africa (GCC and Rest of MEA)
6.6.1 Middle East and Africa Multiple Sclerosis Drugs Market, by Molecule Type, 2015-2025 (US$)
6.6.2 Middle East and Africa Multiple Sclerosis Drugs Market, by Route of Administration, 2015-2025 (US$)
6.6.3 Middle East and Africa Multiple Sclerosis Drugs Market, by Country, 2015-2025 (US$)
Chapter 7 Company Profiles
7.1 Abbvie, Inc.
7.2 Acorda Therapeutics
7.3 Acorda Therapeutics, Inc.
7.4 Bayer HealthCare
7.5 Biogen
7.6 Genzyme (Sanofi)
7.7 GlaxoSmithKline plc.
7.8 Merck Serono
7.9 Novartis International AG
7.10 Pfizer Inc.
7.11 Teva Pharmaceutical
List Of Table :
TABLE 1 Market Positioning of Key Players in Global Multiple Sclerosis Drugs Market
TABLE 2 Global Multiple Sclerosis Drugs Market, by Molecule Type, 2015 – 2025 (US$ Bn)
TABLE 3 Top 3 Countries in Global Multiple Sclerosis Drugs Market, 2015 – 2025 (US$ Bn)
TABLE 4 Global Multiple Sclerosis Drugs Market, by Route of Administration, 2015 – 2025 (US$ Bn)
TABLE 5 Top 3 Countries in Global Multiple Sclerosis Drugs Market, 2015 – 2025 (US$ Bn)
TABLE 6 Global Multiple Sclerosis Drugs Market, by Geography, 2015 – 2025 (US$ Bn)
TABLE 7 North America Multiple Sclerosis Drugs Market, by Molecule Type, 2015-2025 (US$ Bn)
TABLE 8 North America Multiple Sclerosis Drugs Market, by Route of Administration, 2015-2025 (US$ Bn)
TABLE 9 North America Multiple Sclerosis Drugs Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 10 Europe Multiple Sclerosis Drugs Market, by Molecule Type, 2015-2025 (US$ Bn)
TABLE 11 Europe Multiple Sclerosis Drugs Market, by Route of Administration, 2015-2025 (US$ Bn)
TABLE 12 Europe Multiple Sclerosis Drugs Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 13 Asia Pacific Multiple Sclerosis Drugs Market, by Molecule Type, 2015-2025 (US$ Bn)
TABLE 14 Asia Pacific Multiple Sclerosis Drugs Market, by Route of Administration, 2015-2025 (US$ Bn)
TABLE 15 Asia Pacific Multiple Sclerosis Drugs Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 16 Latin America Multiple Sclerosis Drugs Market, by Molecule Type, 2015-2025 (US$ Bn)
TABLE 17 Latin America Multiple Sclerosis Drugs Market, by Route of Administration, 2015-2025 (US$ Bn)
TABLE 18 Latin America Multiple Sclerosis Drugs Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 19 Middle East and Africa Multiple Sclerosis Drugs Market, by Molecule Type, 2015-2025 (US$ Bn)
TABLE 20 Middle East and Africa Multiple Sclerosis Drugs Market, by Route of Administration, 2015-2025 (US$ Bn)
TABLE 21 Middle East and Africa Multiple Sclerosis Drugs Market, by Region, 2015 – 2025 (US$ Bn)
TABLE 22 Abbvie, Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 23 Acorda Therapeutics: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 24 Acorda Therapeutics, Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 25 Bayer HealthCare: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 26 Biogen: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 27 Genzyme (Sanofi): Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 28 GlaxoSmithKline plc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 29 Merck Serono: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 30 Novartis International AG: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 31 Pfizer Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 32 Teva Pharmaceutical: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
List Of Figures :
FIG. 1 Multiple Sclerosis Drugs Market: Research Methodology
FIG. 2 Global Multiple Sclerosis Drugs Market, by Molecule Type, 2016 (US$ Bn)
FIG. 3 Global Multiple Sclerosis Drugs Market, by Route of Administration, 2016 (US$ Bn)
FIG. 4 Global Multiple Sclerosis Drugs Market Share, by Geography, 2016 (Value %)
FIG. 5 Attractive Investment Proposition: Global Multiple Sclerosis Drugs Market, by Geography, 2016
FIG. 6 Global Multiple Sclerosis Biologics Market, 2015 – 2025 (US$ Bn)
FIG. 7 Global Multiple Sclerosis Small Molecules Market, 2015 – 2025 (US$ Bn)
FIG. 8 Global Multiple Sclerosis Oral Therapeutic Drugs Market, 2015 – 2025 (US$ Bn)
FIG. 9 Global Multiple Sclerosis Parenteral Therapeutic Drugs Market, 2015 – 2025 (US$ Bn)
Based on molecule type, the global multiple sclerosis drugs market is segmented as follows:
Multiple sclerosis (MS) is an autoimmune disease in which the myelin sheath of nerve cells in the brain and spinal cord are damaged. MS organizations have estimated that 2.3 million people are living with the disease worldwide. There is no cure for MS but various disease management options are available in market. These medications are used to slow disease progression and lower relapse rate. For the purpose of the study market is segmented on the basis of molecule type such as biologics and small molecules. It is observed that, in the base year 2016, biologics was major revenue generating segment. Biologics such as Avonex, Betaseron, CinnoVex, Extavia, Rebif, and Tysabri are widely used in the market. However, it is estimated that small molecule segment will show highest growth during forecast period due to the expected launch of various oral formulations of small molecules such as ALKS-8700, OS-440, RPC-1063, ACT-128800 and BAF312.
Based on route of administration, the global multiple sclerosis drugs market is segmented as follows:
Multiple sclerosis (MS) is a chronic demyelinating inflammatory disease of the central nervous system, it is a most common neurological disease of adults age between 20-40, affecting over 450,000 patients in the United States and over 3.5 million patients worldwide. Currently, there is no cure for MS but various disease management options are available in market. These medications are used to slow disease progression and lower relapse rate. It is observed that in the base year 2016, parenteral therapeutic drugs were major revenue generating segment because some major parenteral drugs such as Avonex, Betaseron, Copaxone, Extavia, Glatopa, Plegridy, Rebif, Zinbryta are driving the market growth. However, it is estimated that oral therapeutics drugs will show significant market growth during forecast period due to the expected launch of oral pipeline molecule such as OS-440, MD1003, Cladribine, CS-0777, Gilenya, RPC-1063, RPC-1063 and ACT-128800.
For the purpose of this study, the global multiple sclerosis drugs market is categorized into:
In the base year 2016, North America dominated the multiple sclerosis drugs market and it is estimated to show fastest market growth during forecast period. Some factors such as increasing incidence of MS, technological advances, upsurge in funding by government agencies and private organizations in healthcare system and higher cost of treatment medication are prime factors that fueling the growth of multiple sclerosis drugs market in North America. According to the Multiple Sclerosis Foundation, more than 400,000 people in the United States and about 2.5 million people around the world have MS; about 200 new cases are diagnosed each week in the United States. MS is an expensive disease to treat; it is studied that direct and indirect health care costs range from US$ 8,528 to US$ 54,244 per patient per year in the United States. Europe is the second largest revenue generating regional market for multiple sclerosis. Existence of higher number of target population is driving the market growth in Europe. The Multiple Sclerosis Foundation estimates that the incidence of MS is higher in colder climates, people of Northern European descent have the highest risk of developing MS, no matter where they live.
